Valuation: Fluicell AB

Market Cap 38.46M 3.96M 3.47M 3.2M 3M 5.62M 374M 5.73M 14.88M 185M 14.87M 14.54M 640M P/E 2024
-1.1x
P/E 2025 -1.65x
Enterprise Value 36.2M 3.73M 3.27M 3.01M 2.82M 5.29M 352M 5.4M 14.01M 174M 13.99M 13.69M 602M EV / Sales 2024
0.71x
EV / Sales 2025 0.75x
Free-Float
75.27%
Yield 2024 *
-
Yield 2025 -
1 day-3.11%
1 week-19.31%
Current month-48.15%
1 month-51.05%
3 months+159.26%
6 months+147.79%
Current year+180.00%
1 week 26.6
Extreme 26.6
35.9
1 month 26.6
Extreme 26.6
60
Current year 7.65
Extreme 7.65
67.2
1 year 7.45
Extreme 7.45
67.2
3 years 7.45
Extreme 7.45
643.3
5 years 7.45
Extreme 7.45
12,145
10 years 7.45
Extreme 7.45
15,330
Manager TitleAgeSince
Chief Executive Officer 42 2022-12-31
Chief Tech/Sci/R&D Officer 46 2016-12-31
Director of Finance/CFO 56 2023-06-30
Director TitleAgeSince
Director/Board Member 62 2014-12-31
Director/Board Member 54 2016-12-31
Chairman 61 2015-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-3.11%-19.31%+211.11%-95.27% 3.96M
-0.48%+7.20%-5.65%+3.69% 46.2B
+2.19%+11.71%+393.31%+609.31% 38.71B
+2.53%+13.93%+21.38%-10.96% 31.9B
+1.65%+3.61%+16.04%+55.24% 31.12B
-4.16%-2.58%+8.94%+26.14% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+69.64%+136.34% 15.05B
+1.00%+10.30%+13.31%+23.36% 13.74B
+3.63%+9.53%+103.97%+106.25% 13.42B
Average +0.43%+6.29%+92.45%+94.90% 23.01B
Weighted average by Cap. +0.75%+8.71%+88.75%+138.12%

Financials

2024 2025
Net sales 5.35M 551K 483K 445K 417K 781K 51.94M 797K 2.07M 25.67M 2.07M 2.02M 89.02M 15.22M 1.57M 1.37M 1.27M 1.19M 2.22M 148M 2.27M 5.89M 73.05M 5.88M 5.75M 253M
Net income -15.51M -1.6M -1.4M -1.29M -1.21M -2.27M -151M -2.31M -6M -74.44M -6M -5.86M -258M -8.33M -858K -752K -693K -649K -1.22M -80.91M -1.24M -3.22M -39.99M -3.22M -3.15M -139M
Net Debt -15.92M -1.64M -1.44M -1.32M -1.24M -2.33M -155M -2.37M -6.16M -76.43M -6.16M -6.02M -265M -2.26M -233K -204K -188K -176K -330K -21.97M -337K -875K -10.86M -874K -855K -37.64M
Logo Fluicell AB
Fluicell AB is a Sweden-based company within healthcare industry. It commercializes a product portfolio for processing and studying of individual cells, primarily in the field of drug development. The Company’s products comprise research tools BioPen and Dynaflow Resolve. Tools enable researchers to study, process and measure drug impact on individual cells. Also, the Company develops bioprinting technology Biopixlar Retina in both two-dimensional (2D) and three-dimensional (3D) options. Biopixlar Retina creates complex tissue-like structures with control over positioning of individual cells.
Employees
11
Date Price Change Volume
26-06-26 SEK 28.00 -3.11% 5,572
26-06-25 SEK 28.90 -10.80% 12,774
26-06-24 SEK 32.40 +0.31% 20,280
26-06-23 SEK 32.30 -2.42% 4,801
26-06-22 SEK 33.10 -4.61% 5,794
  1. Stock Market
  2. Stocks
  3. FLUI Stock